Navigation Links
Research could lead to new drugs for major diseases

Researchers at the University of Gothenburg, Sweden, are working to develop substances that can prevent parasites, bacteria and fungi from producing essential proteins, research that could, in the long term, lead to new drugs for several major diseases.

The World Health Organization (WHO) has announced that aminoacyl-tRNA synthetases a type of enzyme are important targets for the development of new drugs for several major diseases such as cancer, various parasitic diseases and bacterial and fungal infections.

These enzymes are involved in the production of proteins (protein synthesis) in all organisms. Their job is to ensure that the right amino acid is linked to the growing protein chain. These enzymes are essential for all living organisms.

Challenging research field

Researchers at the University of Gothenburg are currently undertaking basic research in this challenging field. The aim is to prevent the enzyme from producing proteins in bacteria, parasites or fungi, without stopping it from functioning in the human body.

"We're collaborating with researchers in several countries," says researcher Itedale Namro Redwan. "Our role has been to design and to synthesise substances that can be used for the development of drugs against parasitic diseases."

Looking for an effective substance

The enzymes' job of ensuring that the right amino acid is linked to the growing protein chain works in the same way in all types of cell, be they human or parasitic.

"The real challenge is identifying substances that act on enzymes in the parasite alone, without affecting the human enzymes at the same time," says Itedale Namro Redwan, who is making substances that can prevent bacterial and parasitic enzymes from functioning, but do not affect human enzymes. If this proves possible, it will help in the development of drugs for several major diseases.

"One of our main objectives has been to produce potent and selective substances that can be used to gain understanding of how these enzymes work. A greater understanding of their function would contribute to the development of medication for diseases like elephantitis."

Could prevent major diseases

Elephantitis, also known as filiaris, affects more than 120 million people in the developing world, and is caused by a worm that lives in the infected person's lymphatic vessels.

The potentially active molecules are being designed using computer-based molecular modelling techniques, with the resulting molecules subsequently synthesised via various chemical reactions.

"One of the best things about being a medicinal chemist is getting to plan a synthetic pathway that'll result in a specific substance, starting the reaction and then realising that the reaction's has worked," says Itedale Namro Redwan. "Better still is finding out that the molecule has performed as expected in a biological test."

The activity of the synthesised substances is assessed by partners through biological testing on, for example, aminoacyl-tRNA synthetase isolated from E. coli or filiaris parasites.

Contact: Itedale Namro Redwan
University of Gothenburg

Related biology technology :

1. Wolters Kluwer Research Now Available via Bloomberg Tradebook
2. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
3. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
4. Researching graphene nanoelectronics for a post-silicon world
5. In new quantum-dot LED design, researchers turn troublesome molecules to their advantage
6. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
7. New research points to benefits of innovative cobasĀ® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
8. Multidisciplinary team of researchers develop world’s lightest material
9. K computer research results awarded ACM Gordon Bell Prize
10. ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market
11. Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
Post Your Comments:
Related Image:
Research could lead to new drugs for major diseases
(Date:11/27/2015)... /PRNewswire/--  Mallinckrodt plc (NYSE: MNK ), a ... closed the sale of its global contrast media and ... in a transaction valued at approximately $270 million. The ... total of approximately 1,000 employees spread across the globe, ... area. This entire workforce and the manufacturing ...
(Date:11/26/2015)... 26, 2015 ... Accutest Research Laboratories, a leading independent ... (CRO), has formed a strategic partnership ... Temple Health for joint work on ... ) , --> ...
(Date:11/25/2015)... ANNAPOLIS, Md. , Nov. 25, 2015  PharmAthene, ... of Directors has adopted a stockholder rights plan (Rights ... its net operating loss carryforwards (NOLs) under Section 382 ... --> --> PharmAthene,s use of its ... an "ownership change" as defined in Section 382 of ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... HART ), a biotechnology company developing bioengineered organ implants ... McGorry will present at the LD Micro "Main ... 2:30 p.m. PT. The presentation will be webcast live ... Management will also be available at the conference for ...
Breaking Biology Technology:
(Date:10/26/2015)... 2015  Delta ID Inc., a company focused on ... PC devices, announced its ActiveIRIS® technology powers the iris ... launched by NTT DOCOMO, INC in Japan ... smartphone to include iris recognition technology, after a very ... in May 2015, world,s first smartphone to have this ...
(Date:10/23/2015)... GOLETA, California , October 23, 2015 ... Instruments (SMI) announce a mobile plug and play integration ... interactive real-world tasks SensoMotoric Instruments (SMI) ... established wearable solutions for eye tracking and physiological data ... with SMI Eye Tracking Glasses 2w and ...
(Date:10/22/2015)... -- Synaptics (NASDAQ: SYNA ), a leading developer of human interface ... 30, 2015. --> --> ... percent over the comparable quarter last year to $470.0 million. Net ... or $0.62 per diluted share. --> ... fiscal 2016 grew 39 percent over the prior year period to ...
Breaking Biology News(10 mins):